Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines
Plus: Pfizer And BioNTech Strike UK Deal
Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.